Business Context and Reporting Period
Galectin Therapeutics Inc. is a development-stage biotechnology company developing galectin-targeting therapies for cancer and fibrotic disease. This unaudited Form 10-Q covers the three and six months ended June 30, 2012, with comparative periods ended June 30, 2011, and a balance-sheet comparison to December 31, 2011.
Lead programs were GM-CT-01 for cancer and GR-MD-02 for liver fibrosis and fatty liver disease. The company began trading on the NASDAQ Capital Market in March 2012 under the symbol GALT.
Financial Results and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Research and development expense | $1.215 million | $2.116 million |
| General and administrative expense | $1.453 million | $2.505 million |
| Total operating expenses | $2.668 million | $4.621 million |
| Net loss | $2.660 million | $4.610 million |
| Net loss applicable to common stockholders | $2.984 million | $5.188 million |
| Basic and diluted loss per share | $0.19 | $0.36 |
| Net cash used in operating activities | Not separately provided | $3.670 million |
The company reported no revenue and remains dependent on external financing. Profit margins are not meaningful because operations generated losses and no reported revenue. Cumulative net loss applicable to common stockholders since inception was $74.6 million.
At June 30, 2012, cash and cash equivalents were $13.130 million, compared with $6.397 million at December 31, 2011. Total assets were $13.322 million and total current liabilities were $1.780 million. Redeemable convertible preferred stock had carrying values totaling $6.636 million, with stated redemption values totaling approximately $10.366 million. The filing reports no outstanding debt instruments at June 30, 2012.
Net cash provided by financing activities was $10.403 million for the six months, primarily from the March 2012 public offering. The company issued 2,666,722 common shares and warrants to purchase 1,333,361 shares, generating gross proceeds of $12.0 million and net proceeds of $10.4 million.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense increased 4% to $2.116 million from $2.035 million, primarily due to increased clinical manufacturing and preclinical activity.
- Six-month general and administrative expense decreased 16% to $2.505 million from $2.969 million, mainly due to lower business-development, legal, and stock-based compensation costs.
- Six-month total operating expenses declined 8% to $4.621 million from $5.004 million.
- Six-month net loss decreased to $4.610 million from $5.519 million; net loss applicable to common stockholders decreased to $5.188 million from $6.656 million.
- Operating cash use increased to $3.670 million from $2.883 million despite the lower net loss, reflecting operating cash requirements and timing of payments.
- Cash increased by $6.733 million, primarily because the March offering more than offset operating cash use.
- Common shares outstanding increased to 15,819,346 from 12,919,538 at December 31, 2011. Outstanding warrants and options totaled approximately 10.7 million shares at June 30, 2012, before considering preferred-stock conversion rights.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that available cash at June 30, 2012 was sufficient to fund operations through 2013, but additional financing will be required. If financing is not obtained or products do not reach market before the end of 2013, the company may need to cease operations or seek bankruptcy protection.
- GM-CT-01 entered a Phase I/II melanoma trial in Belgium, with the first patient enrolled in May 2012. Stage 1, involving 12 evaluable patients, was expected to be completed by the end of the second quarter of 2013. Stage 2 was estimated to require approximately $1.0 million of company funding.
- GR-MD-02 was in preclinical toxicology and pharmacology studies. Management targeted an FDA IND by the end of 2012, a Phase I NASH trial in early 2013, and a Phase II trial by the end of 2013, subject to regulatory and development risks.
- The company has not generated revenue. A $200,000 payment from PROCAPS remains deferred revenue pending completion of contractual deliverables. Potential future revenue from the PROCAPS agreement was not included in financing plans.
- A former CEO initiated arbitration seeking payment of a $1.0 million severance obligation. The company has accrued the amount but disputes that the contractual milestone requiring payment has occurred.
- In July 2012, after the reporting date, the company received notice of issuance of a U.S. patent covering methods related to galectin inhibitor compounds for liver fibrosis and related diseases.
- The company identified typical development-stage risks, including clinical-trial failure or delay, regulatory nonapproval, intellectual-property challenges, dependence on collaborators and outside capital, competition, limited trading volume, and stock-price volatility.
- Management reported that disclosure controls and procedures were effective as of June 30, 2012, with no material changes to internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Whether the $13.130 million cash balance and stated runway through 2013 remain adequate relative to clinical, manufacturing, and corporate spending.
- The status, enrollment, safety, and efficacy results of the GM-CT-01 melanoma trial and the regulatory progress of GR-MD-02.
- The company’s ability to obtain additional financing on acceptable terms before cash is exhausted.
- The outcome and timing of the $1.0 million severance arbitration.
- The potential dilution from outstanding warrants, options, preferred-stock conversion rights, and future equity financings.
- Whether PROCAPS obtains Colombian regulatory approval and whether the agreement produces product sales or royalties.
- The enforceability and commercial significance of the patent issued after the reporting date.